Results of Operations and Financial Condition. On August 13, 2026, Nektar Therapeutics, a Delaware corporation (“Nektar”), issued a press release (the “Press Release”) announcing its financial results for the quarter ended June 30, 2026. A copy of the Press Release is furnished herewith as Exhibit 99.1. The information in this report, including the exhibit hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended,…

interim Chief Financial Officer — Sandra Gardiner: Sandra Gardiner is retiring and stepping down as interim Chief Financial Officer, with Linda Rubinstein succeeding her in the same role.

Entry Into a Material Definitive Agreement. On May 8, 2026, Nektar Therapeutics (the “Company”) entered into an Equity Distribution Agreement (the “Agreement”) with Guggenheim Securities, LLC (“Guggenheim Securities”) and H.C. Wainwright & Co., LLC (“Wainwright”), pursuant to which the Company may offer and sell, from time to time in its sole discretion, shares of its common stock, par value $0.0001 per share (the “Common Stock”) having an aggregate offering price of up to $150,000,000 (the “…

Results of Operations and Financial Condition. On May 7, 2026, Nektar Therapeutics, a Delaware corporation (“Nektar”), issued a press release (the “Press Release”) announcing its financial results for the quarter ended March 31, 2026. A copy of the Press Release is furnished herewith as Exhibit 99.1. The information in this report, including the exhibit hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or…

Entry into a Material Definitive Agreement. On April 21, 2026, Nektar Therapeutics (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC, TD Securities (USA) LLC, and Piper Sandler & Co. (collectively, the “Representatives”) as the representatives of the several underwriters named therein (the “Underwriters”), relating to an underwritten offering (the “Offering”) of 3,532,609 shares (the “Firm Shares”) of the Company’s common stock, $0.0001 p…

Other Events. Phase 2b REZOLVE-AA Results – Blinded 16-Week Treatment Extension Period On April 20, 2026, the Company announced 52-week topline results from the blinded 16-week treatment extension period of its REZOLVE-AA study of rezpegaldesleukin. REZOLVE-AA is a global study being conducted in 92 patients with severe-to-very-severe alopecia areata. During the initial 36-week induction phase, patients were randomized (3:3:2) to receive one of two rezpegaldesleukin doses or placebo, administ…

Results of Operations and Financial Condition. On March 12, 2026, Nektar Therapeutics, a Delaware corporation (“Nektar”), issued a press release (the “Press Release”) announcing its financial results for the quarter ended December 31, 2025. A copy of the Press Release is furnished herewith as Exhibit 99.1. The information in this report, including the exhibit hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amende…

Entry into a Material Definitive Agreement. On February 11, 2026, Nektar Therapeutics (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC, TD Securities (USA) LLC, and Piper Sandler & Co. (collectively, the “Representatives”) as the representatives of the several underwriters named therein (the “Underwriters”), relating to an underwritten offering (the “Offering”) of (i) 6,603,449 shares (the “Firm Shares”) of the Company’s common stock, $0…

Other Events. Phase 2b REZOLVE-AD Results – 36-Week Blinded Maintenance Period On February 10, 2026, the Company announced results from the 36-week blinded maintenance period of its 52-week REZOLVE-AD study of rezpegaldesleukin. The global REZOLVE-AD Phase 2b study enrolled 393 patients with moderate-to-severe atopic dermatitis. Patients were randomized (3:3:3:2) to receive subcutaneous treatment with three doses of rezpegaldesleukin or placebo for a 16-week induction period. Following a 16-w…

Other Events. Phase 2b RESOLVE-AA Topline Results – 36-Week Induction Treatment Period On December 16, 2025, the Company announced topline results from the 36-week induction treatment period for its Phase 2b REZOLVE-AA (alopecia areata) clinical trial. The global Phase 2b study is being conducted in 92 patients with severe-to-very-severe alopecia areata. Patients were randomized (3:3:2) to receive one of two rezpegaldesleukin doses or placebo, administered as a subcutaneous injection twice-mo…

Chief Legal Officer — Mark A. Wilson: Mr. Wilson is stepping down as Chief Legal Officer with a named successor.

Results of Operations and Financial Condition. On November 6, 2025, Nektar Therapeutics, a Delaware corporation (“Nektar”), issued a press release (the “Press Release”) announcing its financial results for the quarter ended September 30, 2025. A copy of the Press Release is furnished herewith as Exhibit 99.1. The information in this report, including the exhibit hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as ame…

Results of Operations and Financial Condition. On August 7, 2025, Nektar Therapeutics, a Delaware corporation (“Nektar”), issued a press release (the “Press Release”) announcing its financial results for the quarter ended June 30, 2025. A copy of the Press Release is furnished herewith as Exhibit 99.1. The information in this report, including the exhibit hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, o…

Entry into a Material Definitive Agreement. On June 30, 2025, Nektar Therapeutics (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC as the representative of the several underwriters named therein (the “Underwriters”), relating to an underwritten offering (the “Offering”) of 4,255,320 shares (the “Firm Shares”) of the Company’s common stock, $0.0001 par value per share (the “Common Stock”). The Company also granted the Underwriters a 30-da…

Other Events. Phase 2b RESOLVE-AD Topline Results On June 24, 2025, the Company announced topline results from its Phase 2b REZOLVE-AD (atopic dermatitis) clinical trial. The global Phase 2b study is being conducted in 393 patients with moderate-to-severe atopic dermatitis. Patients were randomized (3:3:3:2) to receive subcutaneous treatment with three doses of rezpegaldesleukin: a high dose of 24 µg/kg every two weeks (q2w), a middle dose of 18 µg/kg every two weeks (q2w), and a low dose of…

Results of Operations and Financial Condition. On May 8, 2025, Nektar Therapeutics, a Delaware corporation (“Nektar”), issued a press release (the “Press Release”) announcing its financial results for the quarter ended March 31, 2024. A copy of the Press Release is furnished herewith as Exhibit 99.1. The information in this report, including the exhibit hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or…

Other Events. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On April 3, 2025, Nektar Therapeutics (the “Company”) received a notice (the “Notice”) from the Nasdaq Listing Qualifications Department (the “Staff”) of The Nasdaq Capital Market (“Nasdaq”) stating that the Company was not in compliance with Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Rule”) because the Company’s common stock did not maintain a minimum closing bid pri…

Results of Operations and Financial Condition. On March 12, 2025, Nektar Therapeutics, a Delaware corporation (“Nektar”), issued a press release (the “Press Release”) announcing its financial results for the quarter ended December 31, 2024. A copy of the Press Release is furnished herewith as Exhibit 99.1. The information in this report, including the exhibit hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amende…

Other Events. On February 24, 2025, Nektar Therapeutics, a Delaware corporation (“Nektar”), announced that it has entered into a new clinical trial agreement with TrialNet, an international clinical trial network at the forefront of diabetes research, to evaluate Nektar’s rezpegaldesleukin in patients with new onset stage 3 type 1 diabetes mellitus. Under the agreement, TrialNet will conduct and fund the study. TrialNet is sponsored and funded by the National Institutes of Health, primarily t…

Completion of Acquisition or Disposition of Assets. On December 2, 2024, Nektar Therapeutics, a Delaware corporation (“ Nektar ”), completed its previously announced disposition to an affiliate of Ampersand Management LLC d/b/a Ampersand Capital Partners, a Delaware limited liability company (said affiliate, “ Purchaser ”), of Nektar’s manufacturing facility located in Huntsville, Alabama and certain other manufacturing assets related thereto, as well as Purchaser’s assumption of certain rela…

Results of Operations and Financial Condition. On November 7, 2024, Nektar Therapeutics, a Delaware corporation (“Nektar”), issued a press release (the “Press Release”) announcing its financial results for the quarter ended September 30, 2024. A copy of the Press Release is furnished herewith as Exhibit 99.1. The information in this report, including the exhibit hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as ame…

Entry into a Material Definitive Agreement. On November 1, 2024, Nektar Therapeutics, a Delaware corporation (“ Nektar ”), entered into an Asset Purchase Agreement (the “ APA ”) with an affiliate of Ampersand Management LLC d/b/a Ampersand Capital Partners, a Delaware limited liability company (said affiliate, “ Purchaser ”). Pursuant to the APA, on the terms and subject to the conditions set forth therein, Nektar has agreed to sell to Purchaser, and Purchaser has agreed to purchase from Nekt…

Results of Operations and Financial Condition. On August 8, 2024, Nektar Therapeutics, a Delaware corporation (“Nektar”), issued a press release (the “Press Release”) announcing its financial results for the quarter ended June 30, 2024. A copy of the Press Release is furnished herewith as Exhibit 99.1. The information in this report, including the exhibit hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, o…

Results of Operations and Financial Condition. On May 9, 2024, Nektar Therapeutics, a Delaware corporation (“Nektar”), issued a press release (the “Press Release”) announcing its financial results for the quarter ended March 31, 2024. A copy of the Press Release is furnished herewith as Exhibit 99.1. The information in this report, including the exhibit hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or…

Results of Operations and Financial Condition. On March 4, 2024, Nektar issued a press release (the “Press Release”) announcing its financial results for the quarter and year ended December 31, 2023. A copy of the Press Release is furnished herewith as Exhibit 99.1. The information in this report, including the exhibit hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilitie…